UNLIMITED FREE ACCESS TO THE WORLD'S BEST IDEAS

close
Already an Engineering360 user? Log in.

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

Customize Your Engineering360 Experience

close
Privacy Policy

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

CLSI I/LA21

Clinical Evaluation of Immunoassays; Approved Guideline

active, Most Current
Buy Now
Organization: CLSI
Publication Date: 1 August 2008
Status: active
Page Count: 72
scope:

This document provides specific recommendations for the clinical evaluation of new immunoassays and new applications of existing assays, as well as multiple assay formats and their uses. It focuses on unique characteristics of immunoassays, and provides a guide to designing, executing, and analyzing a clinical evaluation.

The intended users of this guideline are developers of "in-house" assays for institutional use, developers of assays used for monitoring pharmacologic effects of new drugs or biologics, and clinical and regulatory personnel responsible for commercializing products.

Document History

CLSI I/LA21
August 1, 2008
Clinical Evaluation of Immunoassays; Approved Guideline
This document provides specific recommendations for the clinical evaluation of new immunoassays and new applications of existing assays, as well as multiple assay formats and their uses. It focuses...

References

Advertisement